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The purpose of this study is to investigate the clinical and histopathologic significance of hypoxia-inducible-factor 1a (HIF-1a)
expression in oesophageal squamous cell carcinoma. One hundred and thirty surgically resected specimens of OSCC were
immunohistochemically assessed for HIF-1a expression with monoclonal antibody. High HIF-1a immunostaining was detected in 40
specimens . The percentage of high HIF-1a expression cases increased with tumour stage according to pTNM system. High HIF-1a
expression correlated with pTNM stage , depth of tumour invasion, lymph node metastasis, distant metastasis, lymphatic invasion and
positive surgical margin. The overall survival rate was worse in patients with high HIF-1a pattern than in patients with low-expression
pattern. Univariate analyses identified high HIF-1a positivity, depth of tumour invasion, lymph node metastasis, distant metastasis,
lymphatic invasion, and a positive surgical margin as risk factors. Multivariate analyses indicated that depth of tumour invasion, lymph
node metastasis and positive surgical margin, but not HIF-1a, were independent prognostic factors. Survival in patients with a high
HIF-1a expression was significantly worse than in those with low expression in patient treated with adjuvant therapy.
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Oesophageal cancer is an aggressive tumour with a poor prognosis.
Although diagnostic and surgical techniques have been advanced,
survival rates have not been improved in the last decade, and the 5-
year survival rate of patients with surgically treated oesophageal
cancer remains less than 50% in spite of three-field lymph node
dissection and combination chemotherapy and radiotherapy
(Torres et al, 1999; Adham et al, 2000; Ando et al, 2000; Collard
et al, 2001).
The choice of therapeutic strategy is based primarily on whether
lymph node metastasis has occurred. The presence of lymph node
metastasis is the most important determinant of outcome (Ando
et al, 2000; Kusumi et al, 2000). Patients with oesophageal cancer
without nodal metastasis have a lower rate of recurrence after
operation than those with nodal metastasis (Kato et al, 1996;
Matsubara et al, 1996). However, it is difficult to determine
whether lymph node metastases have occurred preoperatively in
spite of new imaging techniques. Thus, the identification of a
marker that predicts lymph node metastasis, and hence prognosis,
is highly desirable.
A hypoxic microenvironment is characteristic of many solid
tumours. In the absence of neovascularisation, tumours cannot
grow beyond several cubic millimeters, because the diffusion of
oxygen, glucose, and other nutrients from blood vessels is limited
(Dang and Semenza, 1999). Cancer cell proliferation may outpace
the rate of angiogenesis, resulting in tissue hypoxia. To surmount
these limitations, the tumour needs to acquire abilities that allow it
to adapt to a hypoxic microenvironment (Maxwell et al, 1999;
Zhong et al, 1999).
Hypoxia-inducible-factor 1a(HIF-1a)is a 120kDa nuclear pro-
tein. Hypoxia-inducible-factor 1 is a heterodimer, consisting of an
a and a b subunit, both belonging to the basic–helix–loop–helix
Per-aryl hydrocarbon receptor nuclear translocator-Sim (PAS)
family of transcription factors (Wang et al, 1995). Hypoxia-
inducible-factor-1 is an important component of a widely
operative transcriptional response, activated by hypoxia, cobaltous
ions, and iron chelation. Hypoxia-inducible-factor 1 activates
transcription of hypoxia-inducible genes, including those encoding
erythropoietin (Wang and Semenza 1993), vascular endothelial
growth factor (VEGF) (Forsythe et al, 1996), heme oxygenase-1
(Hoetzel et al, 2001), inducible nitric oxide synthase (Jung et al,
2000), and the glycolytic enzymes aldolase A, enolase 1, lactate
dehydrogenase A (Semenza et al, 1996), phosphofructokinase I
(Minchenko et al, 2002), and phosphoglycerate kinase I (Li et al,
1996). The C-terminal of HIF-1a binds to p300, and p300/CBP-HIF
complexes participate in the induction of hypoxia-responsive
genes, including VEGF (Arany et al, 1996). Received 4 October 2002; revised 12 March 2003; accepted 5 June 2003
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yInduction of HIF-1a in response to hypoxia is instantaneous,
and it can be expressed very early in carcinogenesis, before
histologic evidence of angiogenesis or invasion exists (Ryan et al,
2000).
It has been shown that HIF-1a is a key player in the cancer cells
response to low-oxygen tension in a variety of physiologic
processes including embryogenesis (Ryan et al, 2000), angiogen-
esis, tumorigenesis (Maxwell et al, 1997) and metastases (Zhong
et al, 1999). Moreover, hypoxic regions have been shown to be
both chemo- and radiation resistant (Teicher, 1994; Aebersold et al,
2001; Koukourakis et al, 2001).
In the current study, we examined archival material from 130
surgical specimens of oesophageal squamous cell carcinoma
(OSCC) for HIF-1a immunoreactivity. The purpose was to
determine the correlation between HIF-1a immunoreactivity and
clinical and histopathologic factors.
MATERIALS AND METHODS
Patients and tissue samples
Surgical specimens were collected from 130 patients with primary
OSCC, who underwent radical total oesophagectomy and three-
field lymph node dissection from 1989 to 1999 at the Department
of Surgical Oncology of Hokkaido University Hospital, Hokkaido
Gastroenterology Hospital, or Teine Keijinkai Hospital. Cases of
in-hospital death were excluded. The clinicopathologic stage was
determined according to the TNM classification system of the
International Union Against Cancer (UICC) (Sobin and Wittekind,
1997).
Immunohistochemistry
The expression of HIF-1a was determined immunohistochemically
in paraffin-embedded specimens fixed in 10% formalin. Histologic
slides, 4mm in thickness, were deparaffined in xylene and
rehydrated through a series of graded ethanol. Endogenous
peroxidase activity was blocked by incubation in 3% hydrogen
peroxide in methanol for 10min. The sections were washed twice
in phosphate-buffered saline (PBS) and incubated with 10%
normal goat serum (Histofine SAB-PO kit, Nichirei Corporation,
Tokyo, Japan) for 30min. The slides were then exposed overnight
to a monoclonal antibody against HIF-1a(HIF-1aAb-4, NEO
MARKERS, Fremont, CA, USA) at a dilution of 1:400 at 41C. After
washing in PBS, a biotinylated goat antibody to mouse immu-
noglobulin (Histofine SAB-PO kit, Nichirei Corporation) was
applied, followed by incubation at room temperature for 60min.
The immunohistochemical reactions were developed in freshly
prepared 3,30-diamino-benzidine tetrahydrochloride (Histofine
SAB-PO kit, Nichirei Corporation). Slides were counterstained in
haematoxylin and coverslipped in a systemic mounting medium.
Tissue samples incubated with nonimmune serum served as
negative controls. Immunostaining was evaluated in three visual
fields at a power of  200 under an Olympus microscope
(Olympus Optical, Tokyo, Japan).
Tumour cell immunoreactivity to HIF-1a protein was scored
based on the number of cells exhibiting the nuclear or cytoplasmic
staining using the following classification system:  , no staining;
1þ, nuclear staining in less than 1% of cells; 2þ, nuclear staining
in 1%–10% of cells and/or with weak cytoplasmic staining; 3þ,
nuclear staining in 10% to 50% of cells and/or with distinct
cytoplasmic staining; 4þ, nuclear staining in more than 50% of
cells and/or with strong cytoplasmic staining. Hypoxia-inducible-
factor 1a 3þand 4þwere considered high expression patterns
while the remaining cases were considered to be low expression.
All specimens were evaluated by three investigators who were
blinded to the patients’ clinical information.
Statistical analysis
Either the w
2 test or Fisher’s exact test was used to analyse the
correlation between HIF-1a expression and clinicopathologic
features. The cumulative survival rate was calculated by the
Kaplan–Meier method, and the significance of differences in
survival was analysed by the log-rank test. The univariate and
multivariate analyses were performed using the Cox proportional
hazard regression model; Po 0.05 was considered significant in all
analyses. Computations were performed using the Statview J
version 4.5 (SAS Institute, Inc., Cary, NC, USA) software package.
RESULTS
Patient factor
Specimens from 130 patients were included in the current study
(113 male and 17 female patients). The median patient age was 63
years (range, 38–82 years). A relatively large number of patients
had early-stage disease (81 patients, 62%). Sixty-six patients (51%)
had lymph node metastases and 22 patients (17%) had distant
nodal metastases. No patient had distant organ metastasis at the
time of operation. The study population had the following
performance status (PS): PS0, 114 patients; PS1, 15 patients; and
PS2, one patient. Following radical operation, adjuvant therapy
was administered to 52 patients (Stage I; seven cases, Stage II; 23
cases; Stage III; 11 cases, and Stage IV; 11 cases). Chemotherapy,
radiotherapy, and chemoradiotherapy were treated in 12, 18, and
22 patients, respectively (Table 1). The median follow-up period
was 29 months (range, 2–114 months).
Table 1 Characteristics of 130 patients with OSCC
Characteristics Number of patients
Gender
Male 113
Female 17
Age
o60 44
^60 86
Pathological stage(UICC)
I4 0
IIA 21
IIB 20
III 29
IVA 8
IVB 12
Primary tumour
T1 56
T2 16
T3 46
T4 12
Regional lymph node
N0 64
N1 66
Distant Metastasis
M0 108
M1 22
Histological type
G1 31
G2 63
G3 36
Performance status
P0 114
P1 15
P2 1
Adjuvant therapy
Chemotherapy 12
Radiotherapy 18
Chemoradiotherapy 22
None 78
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A total of 130 OSCCs were grouped as 42 HIF-1a negative tumours;
15 HIF-1a 1þtumours; 33 HIF-1a 2þtumours; 30 HIF-1a
3þtumours; and 10 HIF-1a 4þtumours (Figure 1). Thus, 40
tumours (30.8%) were classified as showing high HIF-1a expression.
The frequency of high HIF-1a expression increased with tumour
stage according to pTNM system: 15.0% of stage I (six of 40 cases),
Figure 1 Representative photomicrographs of immunohistochemical staining of HIF1a ( 200). Tumour cell immunoreactivity was scored based on
nuclear and cytoplasmic staining. (A)  , no staining (B)1þ, nuclear staining in less than 1% of cells (C) nuclear staining in 1-10% of cells and/or with weak
cytoplasmic staining (D)3þ, nuclear staining in 10-50% of cells and/or with distinct cytoplasmic staining, (E)4þ, nuclear staining in more than 50% of cells
and/or with strong cytoplasmic staining. (F) HIF-1a-positive cells are already found in carcinoma in situ.
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cases), and 50.0% of stage IV (10 of 20 cases; Table 2).
High HIF-1a expression correlated with the depth of tumour
invasion (P¼0.0186), lymph node metastasis (P¼0.0035), distant
metastasis (P¼0.0320), pTNM stage (P¼0.0019), lymphatic
invasion (P¼0.0492), and positive surgical margin (P¼0.0156)
(Table 3).
HIF-1a immunoreactivity had already been identified in
carcinoma in situ of oesophagus (Figure 1F).
Kaplan-Meier survival analysis
The overall 5-year survival rate was 50.4%. The survival curve of
patients with a high HIF-1a expression tumours was worse than
that of patients with low-expression tumours (log-rank test,
P¼0.0007; Figure 2).
Univariate survival analysis
Univariate analysis performed by Cox regression identified depth
of tumour invasion (Po0.0001), distant metastasis (P¼0.0002),
lymph node metastasis (Po0.0001), lymphatic invasion
(P¼0.0021), positive surgical margin (Po0.0001), and High
HIF-1a expression (P¼0.0011) as correlating with survival
(Table 4).
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Figure 2 Kaplan–Meier overall survival curves of patients with OSCC
with and without high HIF-1a expression. P¼0.0007 by the log-rank test.
Table 3 Correlation between clinicopathologic features
a and HIF 1a
expression in surgical specimens of OSCC
HIF-1a expression
Low High
Variable (n¼40) (n¼90) P-value
Gender
Male 34 79 0.6646
Female 6 11
Age
^60 22 64 0.0732
o60 18 26
Double cancer
Yes 7 19 0.6347
No 33 71
p-Stage
I–II 17 64 0.0019
III–IV 23 26
Histologic grade
G 11 21 0.6107
Others 29 69
Depth of tumour invasion
I–II 16 56 0.0186
III–IV 24 34
Lymph node metastasis
N0 12 52 0.0035
N1 28 38
Distant metastasis
M0 29 79 0.0320
M1 11 11
Tumor size (cm)
o4.5 17 43 0.5774
44.5 23 47
Lymphatic invasion
Positive 27 44 0.0492
Negative 13 46
Vascular invasion
Positive 17 26 0.1279
Negative 23 64
Surgical margin
Positive 6 3 0.0156
Negative 34 87
Adjuvant therapy
Yes 18 34 0.4379
No 22 56
aTNM classification system of the International Union Against Cancer.
Table 2 Hypoxia-inducible factor 1a expression in OSCC by tumour
stage
HIF-1a expression
No. of
Histopathologic
Low expression High expression
high-expression
stage – 1+ 2+ 3+ 4+ cases
Stage I 17 6 11 6 0 6/40(15.0%)
Stage II 17 2 11 9 2 11/41(26.8%)
Stage III 6 3 7 7 6 13/29(44.8%)
Stage IV 2 4 4 8 2 10/20(50.0%)
Table 4 Univariate and multivariate analysis of HIF-1a and pathologic
parameters in patients undergoing curative resection of OSCC
Factor Hazard ratio (95% CI) P-value
Univaruate
HIF-1a 2.629 (1.472–4.694) 0.0011
Gender 2.820 (0.877–9.074) 0.0820
Age 1.013 (0.571–1.800) 0.8815
Double cancer 0.700 (0.339–1.445) 0.3347
p-Grade 1.749 (0.786–3.891) 0.1704
Depth of tumour invasion 4.040 (2.215–7.368) o0.0001
Lymph node metastasis 5.623 (2.843–11.120) o0.0001
Distant Metastasis 3.269 (1.761–6.068) 0.0002
Tumour size 1.729 (0.965–3.099) 0.0658
Lymphatic invasion 2.565 (1.406–4.681) 0.0021
Vascular invasion 1.536 (0.847–2.784) 0.1577
Surgical margin 5.181 (2.288–11.732) o0.0001
Adjuvant therapy 1.018 (0.579–1.789) 0.9501
Multivariate
HIF-1a 1.539 (0.835–2.837) 0.1669
Depth of tumour invasion 2.646 (1.273–5.499) 0.0091
Lymph node metastasis 4.504 (1.984–10.226) 0.0003
Distant metastasis 1.036 (0.493–2.175) 0.9263
Lymphatic invasion 0.691 (0.314–1.520) 0.3580
Surgical margin 2.634 (1.057–6.561) 0.0375
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Cox regression multivariate analysis identified depth of tumour
invasion (P¼0.0091), lymph node metastasis (P¼0.0003), and
positive surgical margin (P¼0.0375), as independent unfavorable
factors. High HIF-1a expression was not an independent
prognostic factor (Table 4).
Kaplan-Meier survival analysis of the patient treated with
adjuvant therapy
Survival in patients with a high HIF-1a expression pattern was
significantly worse than in those with a low-expression pattern in
the patient treated with adjuvant therapy (P¼0.0464; Figure 3).
DISCUSSION
The current results show that
(1) high HIF-1a expression correlates with depth of tumour
invasion, lymph node metastasis, distant metastasis, pTNM
stage, lymphatic invasion and a positive surgical margin, and
(2) survival in patients with a high HIF-1a pattern was worse than
in those with low-expression pattern.
Although HIF-1a was not an independent unfavourable prog-
nostic factor, its expression may strongly influence both tumour
proliferation and lymph node metastasis in OSCC. However, it has
been reported that HIF-1a overexpression was not significantly
correlated with pathological parameter in other cancers, including
head and neck cancer (Hockel et al, 1993; Fyles et al, 1998), and
oropharyngeal cancer (Aebersold et al, 2001). Thus, HIF-1a
expression seems to behave in a tissue-dependent manner.
Hypoxia has been shown to compromise the beneficial effects of
chemotherapeutic drugs (Teicher, 1994) and interfere with the
response of tumours to radiation (Moulder and Rockwell, 1987).
Pretreatment oxygenation levels have been found to be predictive
of the radiation response and survival of patients with cancer of
the uterine cervix (Hockel et al, 1993; Fyles et al, 1998), head and
neck (Gatenby et al, 1988; Nordsmark et al, 1996), oropharyngeal
(Aebersold et al, 2001), and early oesophageal cancer (Koukour-
akis et al, 2001). In the current study, of all pathological stages,
overexpression of HIF-1a in OSCC significantly correlates with an
unfavourable prognosis in the patients treated with adjuvant
therapies.
Preoperative studies on biopsy specimens obtained by endo-
scopy might allow clinicians to make better-informed therapeutic
decisions in conjunction with this marker.
In conclusion, we have suggested that (1) high HIF-1a
expression may be a marker for lymph node metastasis; and (2)
high HIF-1a expression may predict an unfavourable prognosis in
the patient treated with OSCC.
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